Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom

NEW YORK, July 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.

--
Agios Pharmaceuticals, Inc. Analyst Notes
On June 16, 2014, Agios Pharmaceuticals, Inc. (Agios) announced that the Company has been granted the orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML) by the U.S. Food and Drug Administration (FDA). "Receiving orphan drug designation for AG-221 is another important milestone to emerge from our innovative cancer metabolism program," said Chris Bowden, M.D. Chief Medical Officer of Agios. "We are pleased with the progress we are making in the clinic and believe that AG-221, which is expected to enter multiple expansion cohorts in the second half of this year, has the potential to play a significant role in shifting the treatment paradigm for IDH2 mutant positive hematologic cancers from the conventional chemotherapy approach." AG-221 is the Company's oral, first-in-class IDH2 mutant inhibitor that is currently being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation. The full analyst notes on Agios are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/AGIO/report.pdf

--
Alder Biopharmaceuticals Inc. Analyst Notes
On June 18, 2014, Alder BioPharmaceuticals, Inc. (Alder) reported its Q1 2014 financial results. The Company reported total revenues of $4.8 million compared to $4.6 million in Q1 2013. According to the Company, the increase was primarily due to revenue recognized from other collaborations. Net loss for the quarter totaled $5.4 million or $5.38 per share compared to a net loss of $5.7 million, or $5.89 per share in Q1 2013. According to the Company, this decrease was primarily due to lower research and development expenses. As of March 31, 2014, the Company held $12.9 million in cash and cash equivalents compared to $23.2 million as of December 31, 2013. The full analyst notes on Alder are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/ALDR/report.pdf

--
Healthways Inc. Analyst Notes
On June 12, 2014, Healthways Inc. (Healthways) announced that the Company has elected Donato Tramuto, CEO and Chairman of Physicians Interactive, the leading provider of online and mobile clinical resources and solutions for healthcare professionals, as the Chairman of the Board of Directors of the Company. Ben R. Leedle, Jr., President and CEO of Healthways, commented, "We are excited and proud to have Donato as our Board Chairman. As a leader and pioneer in healthcare technologies, with over 30 years working as a healthcare innovator, he has contributed valuable strategic insights to our Board over the last year. We are now looking forward to his leadership of our Board as Healthways continues to provide our comprehensive well-being improvement solutions to health plans, health systems, physicians and employers around the world." Mr. Tramuto has been a member of the Healthways' Board since 2013 and has served on the Compensation Committee since his election to the Board. The full analyst notes on Healthways are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/HWAY/report.pdf

--
NeoGenomics Inc. Analyst Notes
On June 23, 2014, NeoGenomics, Inc. (NeoGenomics) announced that it is raising its previously issued revenue guidance for Q2 2014. The Company now anticipates revenue in the range of $20 to $20.5 million compared with its previous estimate of $18.8 to $19.3 million. Also, the Company reaffirmed its EPS guidance of $0.00 to $0.01 for the quarter. Doug VanOort, the Company's Chairman and CEO, commented, "The growth is geographically broad-based, and is being fueled by the increased size and productivity of our sales team and by new product activity. At the mid-point of the revised guidance range, revenue growth would approximate 30% compared with last year's second quarter. We look forward to sharing our full second quarter financial results, reviewing additional growth initiatives, and updating our full year 2014 revenue and earnings guidance as part of our Q2 Earnings Release on July 17, 2014." The full analyst notes on NeoGenomics are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/NEO/report.pdf

--
Sequenom Inc. Analyst Notes
On June 19, 2014, Sequenom Inc. (Sequenom) and Nicox S.A. announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States. "We are pleased with the timely progress of our partnership with Nicox and we are confident in Nicox's ability to successfully expand access to the RetnaGene portfolio of tests in the ophthalmic arena in the U.S.," stated William Welch, CEO of Sequenom. The portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration (AMD). The full analyst notes on Sequenom are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/SQNM/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED